These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23996142)

  • 1. Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.
    Lien EA; Søiland H; Lundgren S; Aas T; Steen VM; Mellgren G; Gjerde J
    Breast Cancer Res Treat; 2013 Sep; 141(2):243-8. PubMed ID: 23996142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
    Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
    Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.
    Gjerde J; Gandini S; Guerrieri-Gonzaga A; Haugan Moi LL; Aristarco V; Mellgren G; Decensi A; Lien EA
    Breast Cancer Res Treat; 2012 Jul; 134(2):693-700. PubMed ID: 22562123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.
    Gjerde J; Geisler J; Lundgren S; Ekse D; Varhaug JE; Mellgren G; Steen VM; Lien EA
    BMC Cancer; 2010 Jun; 10():313. PubMed ID: 20565970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
    Gjerde J; Hauglid M; Breilid H; Lundgren S; Varhaug JE; Kisanga ER; Mellgren G; Steen VM; Lien EA
    Ann Oncol; 2008 Jan; 19(1):56-61. PubMed ID: 17947222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
    Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
    Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
    Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
    Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
    Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
    BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
    Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
    BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
    Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
    Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
    Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
    Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
    Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
    J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
    Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
    Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.
    Maximov PY; McDaniel RE; Fernandes DJ; Korostyshevskiy VR; Bhatta P; Mürdter TE; Flockhart DA; Jordan VC
    Br J Pharmacol; 2014 Dec; 171(24):5624-35. PubMed ID: 25073551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solanidine Metabolites as Diet-Derived Biomarkers of CYP2D6-Mediated Tamoxifen Metabolism in Breast Cancer Patients.
    Medwid S; Schwarz UI; Choi YH; Keller D; Ross C; Kim RB
    Clin Pharmacol Ther; 2024 Nov; 116(5):1269-1277. PubMed ID: 39039708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
    J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.
    Lim JS; Sutiman N; Muerdter TE; Singh O; Cheung YB; Ng RC; Yap YS; Wong NS; Ang PC; Dent R; Schroth W; Schwab M; Chowbay B
    Br J Clin Pharmacol; 2016 Jun; 81(6):1142-52. PubMed ID: 26799162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
    Antunes MV; Timm TA; de Oliveira V; Staudt DE; Raymundo S; Gössling G; Biazús JV; Cavalheiro JA; Rosa DD; Wallemacq P; Haufroid V; Linden R; Schwartsmann G
    Ther Drug Monit; 2015 Dec; 37(6):733-44. PubMed ID: 25853922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.